- Current report filing (8-K)
July 13 2009 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 8-K
|
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
|
Date of report (date of earliest event reported):
July 13, 2009
|
|
CORE LABORATORIES N.V.
(Exact name of registrant as specified in its charter)
001-14273
(Commission File Number)
The Netherlands
|
Not Applicable
|
(State or other jurisdiction of incorporation or
organization)
|
(I.R.S. Employer Identification No.)
|
|
|
Herengracht 424
|
|
1017 BZ Amsterdam
|
|
The Netherlands
|
Not Applicable
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
Registrant's telephone number, including area code:
(31-20)
420-3191
Check the appropriate below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
___
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
___
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
___
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2 (b))
|
|
|
___
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4 (c))
|
|
|
Item 7.01 Regulation FD Disclosure
On July 13, 2009, Core Laboratories N.V. issued a press release announcing
a quarterly cash dividend equal to $0.10 per share of common stock and a one
time special cash dividend equal to $0.75 per share of common stock for shareholders of record on
July 24, 2009 and
payable August 24, 2009.
The full text of the press release is set forth in Exhibit 99.1 attached
hereto.
The information in this Report and the exhibit attached hereto shall not be
deemed "filed" for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the "Exchange Act"), nor shall they be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly stated by specific reference in such
filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
99.1
|
|
Press release issued on July 13, 2009*
|
* This exhibit is intended to be furnished and shall not be deemed "filed"
for purposes of the Exchange Act.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Core Laboratories N.V.
|
|
|
|
|
|
|
|
Dated: July 13, 2009
|
|
By
|
|
/s/ Richard L. Bergmark
|
|
|
|
|
|
|
Richard L. Bergmark
|
|
|
|
|
|
|
Chief Financial Officer
|
|
|
CORE LABORATORIES N.V.
EXHIBIT INDEX TO FORM 8-K
|
|
|
EXHIBIT NO.
|
|
ITEM
|
|
|
|
99.1
|
|
Press release issued on July 13, 2009*
|
* This exhibit is intended to be furnished and shall not be deemed "filed"
for purposes of the Exchange Act.
Core Laboratories (NYSE:CLB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Core Laboratories (NYSE:CLB)
Historical Stock Chart
From Sep 2023 to Sep 2024